Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours (Q40592751)
scientific article published on May 1, 2003
Language:
(P31) (Q13442814)
(P304) 917-926
(P407) (Q1860)
(P433) 7
(P478) 39
(P577) Thursday, May 1, 2003
(P921) (Q181600)
(Q162555)
(Q323936)
(P953) https://api.elsevier.com/content/article/PII:S0959804903000571?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S0959804903000571?httpAccept=text/plain
(P1433) (Q332260)
(P1476) "Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours" (language: en)
"Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours" (language: en)
(P2093) Eskens FA
F. A L M. Eskens
H. Dumez
R. Hoekstra
A. Perschl
C. Brindley
S. Böttcher
W. Wynendaele
J. Drevs
J. Verweij
A. T. van Oosterom
(P2860) (Q34346157)
(Q41120945)
(Q73316687)
(Q29619681)
(Q61764268)
(Q41646623)
(Q37362821)
(Q36295017)
(Q42809627)
(Q73047951)
(Q41174044)
(Q33180329)
(Q33703528)
(Q73395687)
(Q30625695)
(Q77948497)
other details
description scientific article published on May 1, 2003

External Links